当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies.

Use of GFP-expressing influenza viruses for the detection of influenza virus A/H5N1 neutralizing antibodies.

Abstract：

:The hemagglutination inhibition (HI) assay is used most commonly for the detection of antibodies to influenza viruses. However, for the detection of antibodies to avian influenza viruses of the H5N1 subtype either induced by infection or by vaccination, the HI assay is insensitive. Therefore, the virus neutralization (VN) assay has become the method of choice to detect human serum antibodies directed to these viruses. However, this assay requires a second assay for the detection of residual virus replication, which makes it laborious to perform and less suitable for high throughput testing of large numbers of samples. Here we describe an alternative method for the detection of these antibodies, which is based on the use of reporter viruses that express the green fluorescent protein (GFP) upon infection of target cells. GFP-expressing viruses were generated carrying the HA of a variety of antigenically distinct H5N1 influenza viruses. The method proved easy to perform and could be carried out rapidly. Using a panel of antisera raised against H5N1 influenza viruses, the assay based on GFP expressing viruses was compared with the classical virus neutralization assay and the hemagglutination inhibition assay. In general, the results obtained in these assays correlated well. It was concluded that the assay based on the reporter viruses is an attractive alternative for the classical virus neutralization assay and suitable for large sero-epidemiological studies or for the assessment of vaccine efficacy in clinical trials.

journal_name

Vaccine

journal_title

Vaccine

authors

Rimmelzwaan GF,Verburgh RJ,Nieuwkoop NJ,Bestebroer TM,Fouchier RA,Osterhaus AD

doi

10.1016/j.vaccine.2011.02.082

subject

Has Abstract

pub_date

2011-04-18 00:00:00

pages

3424-30

issue

18

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(11)00330-6

journal_volume

29

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Haemolytic activities and adjuvant effect of Bupleurum chinense saponins on the immune responses to ovalbumin in mice.

    abstract：:In this study, the haemolytic activities of Bupleurum chinense saponins (BCS) and its adjuvant potentials on the immune responses of ICR mice against ovalbumin (OVA) were evaluated. BCS showed a slight haemolytic effect, with its haemolytic percents being 3.32% and 1.19% at the concentrations of 500 and 250 microg/ml,...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.09.030

    authors： Sun HX

    更新日期：2006-02-27 00:00:00

  • The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China.

    abstract：:We aimed to evaluate the present situation and possible risk factors of HBV transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area in northwest China. Two hundred and twenty one HBsAg carrier mothers and 247 children born to them were final...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.09.031

    authors： Li F,Wang Q,Zhang L,Su H,Zhang J,Wang T,Huang D,Wu J,Yan Y,Fan D

    更新日期：2012-11-19 00:00:00

  • Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.

    abstract：BACKGROUND:Chronic hepatitis C virus (HCV) and HIV infections are associated with impaired responses to neo-antigens contained in hepatitis A virus (HAV)/hepatitis B virus (HBV) vaccines, yet responsible mechanisms are unclear. METHODS:ACTG 5232 and CFAR0910 were clinical trials where pre-vaccine levels of plasma IP10...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.12.018

    authors： Shive CL,Judge CJ,Clagett B,Kalayjian RC,Osborn M,Sherman KE,Fichtenbaum C,Gandhi RT,Kang M,Popkin DL,Sieg SF,Lederman MM,Rodriguez B,Anthony DD

    更新日期：2018-01-25 00:00:00

  • Immunity to rubella before and after vaccination against measles, mumps and rubella (MMR) at 12 years of age of the first generation offered MMR vaccination in Sweden at 18 months.

    abstract：:In 1982, a two-dose programme of vaccination against measles, mumps and rubella (MMR) at the ages of 18 months and 12 years was introduced in Sweden. In 1992-3, the first group of children vaccinated at 18 months reached the age of 12, i.e. the time for a second dose. In connection with this 12-year vaccination, 376 c...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究

    doi：10.1016/0264-410x(95)00143-o

    authors： Böttiger M

    更新日期：1995-12-01 00:00:00

  • Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis.

    abstract：:Pharmacological manipulation of the balance between pro- and anti-inflammatory mediators emerges as a key aspect of a successful treatment of sepsis. A murine model of septic shock was developed and chosen conjugates (1a, 1b, 8a, 8c) and analogs (T2) of muramyl dipeptide and tuftsin were tested in this model as prospe...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.11.017

    authors： Wardowska A,Dzierzbicka K,Szaryńska M,Dabrowska-Szponar M,Wiśniewska K,Myśliwski A,Trzonkowski P

    更新日期：2009-01-14 00:00:00

  • Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

    abstract：:The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection p...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.04.058

    authors： Minke JM,Siger L,Cupillard L,Powers B,Bakonyi T,Boyum S,Nowotny N,Bowen R

    更新日期：2011-06-20 00:00:00

  • Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.

    abstract：:Amino acid residues 421-436 constitute a comparatively conserved determinant of gp120 that participates in the binding of host cell CD4 receptors by HIV-1. We compared the immunogenicity of synthetic Cys-gp120 (421-436) conjugated to KLH via the N terminal Cys residue (KLH-I) and gp120 (421-436) extended at its N term...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(02)00504-2

    authors： Karle S,Nishiyama Y,Taguchi H,Zhou YX,Luo J,Planque S,Hanson C,Paul S

    更新日期：2003-03-07 00:00:00

  • Pandemic influenza H1N1 2009 infection in Victoria, Australia: no evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009.

    abstract：:Conflicting findings regarding the level of protection offered by seasonal influenza vaccination against pandemic influenza H1N1 have been reported. We performed a test-negative case control study using sentinel patients from general practices in Victoria to estimate seasonal influenza vaccine effectiveness against la...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.03.055

    authors： Kelly HA,Grant KA,Fielding JE,Carville KS,Looker CO,Tran T,Jacoby P

    更新日期：2011-08-26 00:00:00

  • Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.

    abstract：:A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608-a newly developed live-attenuated zoster vaccine in Korea-relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were e...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2019.04.046

    authors： Choi WS,Choi JH,Jung DS,Choi HJ,Kim YS,Lee J,Jang HC,Shin EC,Park JS,Kim H,Cheong HJ

    更新日期：2019-06-12 00:00:00

  • A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

    abstract：BACKGROUND:FP-01.1 is a novel synthetic influenza A vaccine consisting of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes and is designed to induce an immune response across a broad population. METHODS:FP-01.1 was evaluated for safety and immunogenicity in a randomised...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2014.06.006

    authors： Francis JN,Bunce CJ,Horlock C,Watson JM,Warrington SJ,Georges B,Brown CB

    更新日期：2015-01-03 00:00:00

  • Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women.

    abstract：:Tetanus and diphtheria (Td) antibodies were studied in HIV-1-infected women during puerperium. HIV group (n=61) was compared with Control group (n=101). Twenty-one women from HIV and 13 from Control group who had antibody levels lower than 0.1 IU/mL received a booster with Td vaccine. Antibodies were assessed by doubl...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.03.023

    authors： Bonetti TC,Succi RC,Weckx LY,Tavares-Lopes L,de Moraes-Pinto MI

    更新日期：2004-09-09 00:00:00

  • A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

    abstract：BACKGROUND:To contribute to the global demand for oral cholera vaccine (OCV), the production of Euvichol® was scaled up with elimination of thimerosal. To demonstrate the equivalence of the variations, a study was carried out in the Philippines. METHODS:Healthy male and female adults and children in Manila were random...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2018.05.102

    authors： Russo P,Ligsay AD,Olveda R,Choi SK,Kim DR,Park JY,Park JY,Syed KA,Dey A,Kim YH,Lee SH,Kim J,Chon Y,Digilio L,Kim CW,Excler JL

    更新日期：2018-07-05 00:00:00

  • The impact of administration of conjugate vaccines containing cross reacting material on Haemophilus influenzae type b antibody responses in infants: A systematic review and meta-analysis of randomised controlled trials.

    abstract：BACKGROUND:Protein-polysaccharide conjugate vaccines such as Haemophilus influenzae type b (Hib), meningococcal, and pneumococcal vaccine, induce immunological memory and longer lasting protection than plain polysaccharide vaccines. The most common proteins used as carriers are tetanus toxoid (TT) and cross reacting ma...

    journal_title：Vaccine

    pub_type： 杂志文章,meta分析,评审

    doi：10.1016/j.vaccine.2016.06.038

    authors： Voysey M,Sadarangani M,Clutterbuck E,Bolgiano B,Pollard AJ

    更新日期：2016-07-25 00:00:00

  • Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005.

    abstract：:In order to provide an estimation of the direct and indirect benefits of pneumococcal vaccination with three protein-conjugate pneumococcal vaccines (PCV) we described the epidemiology and mortality from invasive pneumococcal disease (IPD) in Denmark between 2000 and 2005. Approximately 1080 cases were registered annu...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.04.040

    authors： Harboe ZB,Valentiner-Branth P,Benfield TL,Christensen JJ,Hjuler T,Kaltoft M,Krogfelt KA,Lambertsen L,Konradsen HB

    更新日期：2008-07-04 00:00:00

  • Safety and immunogenicity of measles-mumps-rubella vaccine in children with congenital immunodeficiency (DiGeorge syndrome).

    abstract：:Live attenuated vaccines are usually contraindicated in patients with congenital or acquired immunodeficiency. On the other hand, infections due to wild type virus may be particularly severe in patients with low levels of T cells. The aim of the present study was to evaluate safety and immunogenicity of measles-mumps-...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.10.005

    authors： Azzari C,Gambineri E,Resti M,Moriondo M,Betti L,Saldias LR,G Gelli AM,Vierucci A

    更新日期：2005-02-25 00:00:00

  • Two community hepatitis B outbreaks: an argument for vaccinating incarcerated persons.

    abstract：:Current recommendations have not resulted in routine vaccination of correctional facility inmates for hepatitis B. We investigated two hepatitis B outbreaks. Outbreak 1 involved 4 cases epidemiologically linked to persons who had been in jail. Outbreak 2 involved 48 community cases; 69% had a history of incarceration....

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.09.023

    authors： Devasia RA,Jones TF,Kainer MA,Halford S,Sheeler LL,Swift J,Schaffner W

    更新日期：2006-02-27 00:00:00

  • Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.

    abstract：:Intranasal (i.n.) immunization is an effective regimen for the prophylaxis of respiratory diseases in early life. The aim of this study was to assess the need for nasal-associated lymphoid tissue (NALT) and cervical lymph nodes (CLN) in induction of protective immunity following mucosal vaccination of infant mice. We ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.01.027

    authors： Sabirov A,Metzger DW

    更新日期：2008-03-17 00:00:00

  • Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.

    abstract：BACKGROUND AND AIMS:Although two antigenically distinct B strain lineages of influenza have co-circulated globally since the mid-1980s, trivalent influenza vaccines (TIVs) contain only one, resulting in frequent mismatches. This study examined the safety and immunogenicity of an inactivated quadrivalent influenza vacci...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2013.08.069

    authors： Pépin S,Donazzolo Y,Jambrecina A,Salamand C,Saville M

    更新日期：2013-11-12 00:00:00

  • Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.

    abstract：:Humoral responses against extra-cellular HIV-1 Tat may be beneficial as Tat has been implicated in the viral pathogenesis associated with HIV-1 disease progression. We determined the levels of anti-Tat IgG in sera of HIV-1 seropositive individuals from the Rural Clinical Cohort in Uganda using nine different Tat prote...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.09.070

    authors： Campbell GR,Senkaali D,Watkins J,Esquieu D,Opi S,Yirrell DL,Kaleebu P,Loret EP

    更新日期：2007-12-05 00:00:00

  • High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects.

    abstract：:We evaluated a modified HBV regimen in a cohort of HIV-infected subjects in Rio de Janeiro, Brazil. HIV-infected subjects with no serologic evidences of previous hepatitis B infection were immunized with 4 doses (40 microg each) of recombinant hepatitis B vaccine given at 0, 1, 2 and 6 months. Blood samples were colle...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.11.066

    authors： Potsch DV,Oliveira ML,Ginuíno C,Miguel JC,Oliveira SA,Silva EF,Moreira RB,Cruz GV,Oliveira AL,Camacho LA,Barroso PF

    更新日期：2010-02-10 00:00:00

  • Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.

    abstract：:DNA vaccines might offer an alternative to the live smallpox vaccine in providing protective efficacy in an orthopoxvirus (OPV) lethal respiratory challenge model. BALB/c mice were immunised with DNA vaccines coding for 10 different single vaccinia virus (VACV) membrane proteins. After an intranasal challenge with the...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.02.034

    authors： Pulford DJ,Gates A,Bridge SH,Robinson JH,Ulaeto D

    更新日期：2004-09-03 00:00:00

  • Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine.

    abstract：BACKGROUND:In 2003, severe acute respiratory syndrome (SARS) resulted in hundreds of infections and deaths globally. We aim to assess immunogenicity and protective efficacy of purified inactivated Vero-cell SARS vaccine in monkeys. METHODS:The cultures of SARS coronavirus (SARS-CoV) BJ-01 strain infected Vero cells we...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.06.038

    authors： Qin E,Shi H,Tang L,Wang C,Chang G,Ding Z,Zhao K,Wang J,Chen Z,Yu M,Si B,Liu J,Wu D,Cheng X,Yang B,Peng W,Meng Q,Liu B,Han W,Yin X,Duan H,Zhan D,Tian L,Li S,Wu J,Tan G,Li Y,Li Y,Liu Y,Liu H,Lv F

    更新日期：2006-02-13 00:00:00

  • Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.

    abstract：:Financial sustainability plans (FSPs) were developed by over 50 of the world's poorest countries receiving funding support from the Global Alliance for Vaccines and Immunization (GAVI) to introduce new and underused vaccines, injection safety and immunization service support between 2000 and 2006. These plans were ana...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2008.10.014

    authors： Kamara L,Milstien JB,Patyna M,Lydon P,Levin A,Brenzel L

    更新日期：2008-12-02 00:00:00

  • Assessment of potential miRNA biomarkers of VERO-cell tumorigenicity in a new line (AGMK1-9T7) of African green monkey kidney cells.

    abstract：:Patterns of microRNA expression appear to delineate the process of spontaneous neoplastic development-transformation (SPNDT) occurring in the African green monkey kidney (AGMK) VERO cell line (Teferedegne et al., 2010). Analysis of microarray data identified 6 microRNAs whose high-level of expression peaked when the W...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.04.004

    authors： Teferedegne B,Rotroff DM,Macauley J,Foseh G,Lewis G,Motsinger-Rief A,Lewis AM Jr

    更新日期：2017-10-04 00:00:00

  • Vaccination recommendations for patients with neuromuscular disease.

    abstract：:Neuromuscular diseases (NMDs) encompass a broad spectrum of conditions. Because infections may be relevant to the final prognosis of most NMDs, vaccination appears to be the simplest and most effective solution for protecting NMD patients from vaccine-preventable infections. However, very few studies have evaluated th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.09.003

    authors： Esposito S,Bruno C,Berardinelli A,Filosto M,Mongini T,Morandi L,Musumeci O,Pegoraro E,Siciliano G,Tonin P,Marrosu G,Minetti C,Servida M,Fiorillo C,Conforti G,Scapolan S,Ansaldi F,Vianello A,Castaldi S,Principi N,T

    更新日期：2014-10-14 00:00:00

  • Advancing a vaccine to prevent hookworm disease and anemia.

    abstract：:A human hookworm vaccine is under development and in clinical trials in Africa and the Americas. The vaccine contains the Na-APR-1 and Na-GST-1 antigens. It elicits neutralizing antibodies that interfere with establishment of the adult hookworm in the gut and the ability of the parasite to feed on blood. The vaccine t...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.03.078

    authors： Hotez PJ,Beaumier CM,Gillespie PM,Strych U,Hayward T,Bottazzi ME

    更新日期：2016-06-03 00:00:00

  • Influenza vaccination among U.S. pediatric patients receiving care from federally funded health centers.

    abstract：INTRODUCTION:During the 2018-2019 influenza season, vaccination coverage among U.S. children was 62.6%. The purpose of this study was to estimate the prevalence of influenza vaccinations among pediatric patients seen in U.S. health centers, and to explore potential disparities in vaccination coverage among subpopulatio...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.07.021

    authors： Lebrun-Harris LA,Mendel Van Alstyne JA,Sripipatana A

    更新日期：2020-09-03 00:00:00

  • Evaluation of immune response to recombinant potential protective antigens of Mycoplasma hyopneumoniae delivered as cocktail DNA and/or recombinant protein vaccines in mice.

    abstract：:Intramuscular immunization of mice with DNA cocktail vaccines, comprising potential protective antigens P36, P46, NrdF, and P97or P97R1 of Mycoplasma hyopneumoniae, induced strong Th1-polarized immune responses against each antigen, with only P46 eliciting a serum IgG response. Subcutaneous immunization with protein c...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.06.005

    authors： Chen AY,Fry SR,Daggard GE,Mukkur TK

    更新日期：2008-08-12 00:00:00

  • Human papillomavirus (HPV) vaccination and subsequent sexual behaviour: evidence from a large survey of Nordic women.

    abstract：OBJECTIVE:To assess whether recipients and non-recipients of the human papillomavirus (HPV) vaccine subsequently differ in terms of sexual risk taking behaviour. DESIGN:Cross-sectional survey. Sequential analyses constructed from self-reported age at vaccination, age at first intercourse and age at response. SETTING:...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2014.07.025

    authors： Hansen BT,Kjær SK,Arnheim-Dahlström L,Liaw KL,Jensen KE,Thomsen LT,Munk C,Nygård M

    更新日期：2014-09-03 00:00:00

  • Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.

    abstract：:Six peptides, A, B1, B, C, D and E derived from the primary sequence of Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase (SG3PDH) were selected based on lowest homology to human G3PDH and used for immunization of BALB/c mice. Peptides B1 and D induced immunoglobulin (Ig) G1, IgG2a and IgG2b antibodies that...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(03)00180-4

    authors： Tallima H,Montash M,Veprek P,Velek J,Jezek J,El Ridi R

    更新日期：2003-07-04 00:00:00